Nwam LLC Invests $445,000 in DexCom, Inc. $DXCM

Nwam LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 1st quarter, HoldingsChannel reports. The institutional investor bought 7,080 shares of the medical device company’s stock, valued at approximately $445,000.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Reflection Asset Management bought a new position in DexCom during the fourth quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the 1st quarter worth approximately $25,000. CVA Family Office LLC grew its holdings in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth approximately $32,000. Finally, ORG Partners LLC increased its position in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent research reports. TD Cowen restated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Piper Sandler reiterated an “overweight” rating and set a $88.00 price target (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Finally, Truist Financial raised their price objective on shares of DexCom from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $85.36.

DexCom Trading Down 1.7%

Shares of DXCM opened at $76.65 on Friday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The stock has a 50 day simple moving average of $71.16 and a 200-day simple moving average of $68.73. The stock has a market cap of $29.58 billion, a PE ratio of 32.76, a PEG ratio of 1.28 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This represents a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 71,750 shares of company stock valued at $5,163,241. Insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.